Method of driving hollow piles into the ground
    1.
    发明授权
    Method of driving hollow piles into the ground 失效
    将空心桩推入地面的方法

    公开(公告)号:US4637758A

    公开(公告)日:1987-01-20

    申请号:US576995

    申请日:1984-03-16

    摘要: A method and apparatus for driving a hollow pile into the ground. By using a hollow rod having a short auger fixedly secured to a leading end portion thereof, excavated earth and sand are lifted to and around the upper portion of the auger where compressed air is spouted from nozzle orifices formed in the hollow rod thereby lifting the excavated earth and sand through the hollow pile and consequently discharging the same from the hollow pile. As earth and sand are discharged from the hollow pile, the pile is sunk or driven into the ground.

    摘要翻译: 一种用于将空心桩驱动到地面中的方法和装置。 通过使用固定在其前端部分上的具有短螺旋钻的中空杆,挖出的土和砂被提升到螺旋钻的上部并且在螺旋推运器的上部附近,其中压缩空气从形成在中空杆中的喷嘴孔喷出,从而提升挖掘的 通过中空桩将土和沙子排出,从而将其从中空桩排出。 由于沙沙从中空桩排出,桩被沉没或被驱动到地面上。

    Method and apparatus for driving hollow piles into the ground
    2.
    发明授权
    Method and apparatus for driving hollow piles into the ground 失效
    将空心桩推入地面的方法和装置

    公开(公告)号:US4494613A

    公开(公告)日:1985-01-22

    申请号:US357270

    申请日:1982-03-11

    摘要: A method and apparatus for driving a hollow pile into the ground. By using a hollow rod having a short auger fixedly secured to a leading end portion thereof, excavated earth and sand are lifted to and around the upper portion of the auger where compressed air is spouted from nozzle orifices formed in the hollow rod thereby lifting the excavated earth and sand through the hollow pile and consequently discharging the same from the hollow pile. As earth and sand are discharged from the hollow pile, the pile is sunk or driven into the ground.

    摘要翻译: 一种用于将空心桩驱动到地面中的方法和装置。 通过使用固定在其前端部分上的具有短螺旋钻的中空杆,挖出的土和砂被提升到螺旋钻的上部并且在螺旋推运器的上部附近,其中压缩空气从形成在中空杆中的喷嘴孔喷出,从而提升挖掘的 通过中空桩将土和沙子排出,从而将其从中空桩排出。 由于沙沙从中空桩排出,桩被沉没或被驱动到地面上。

    Method of treating depression with certain triazine derivatives
    3.
    发明授权
    Method of treating depression with certain triazine derivatives 失效
    用某些三嗪衍生物治疗抑郁症的方法

    公开(公告)号:US5789407A

    公开(公告)日:1998-08-04

    申请号:US424397

    申请日:1995-04-25

    CPC分类号: C07D487/04 A61K31/53

    摘要: The present invention relates to an antidepressant containing as an active ingredient a triazine derivative or a pharmaceutically acceptable salt thereof, the derivative being represented by the following Formula (I): ##STR1## in which, R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkanoyl; R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a substituted or unsubstituted heterocyclic group; X represents a single bond, O, S, S(O), S(O).sub.2, or NR.sup.4 (in which R.sup.4 represents hydrogen, or substituted or unsubstituted lower alkyl; or R.sup.2 and NR.sup.4 are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group); and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl).

    摘要翻译: PCT No.PCT / JP94 / 01455 Sec。 371日期1995年04月25日 102(e)日期1995年4月25日PCT 1994年9月2日PCT公布。 公开号WO95 / 07282 日期:1995年3月16日本发明涉及含有作为活性成分的三嗪衍生物或其药学上可接受的盐的抗抑郁药,该衍生物由下式(I)表示:其中,R 1表示 氢,取代或未取代的低级烷基或取代或未取代的低级烷酰基; R 2表示氢,取代或未取代的低级烷基,取代或未取代的低级烯基,取代或未取代的环烷基,取代或未取代的芳基,取代或未取代的芳烷基或取代或未取代的杂环基; R3表示取代或未取代的杂环基; X表示单键,O,S,S(O),S(O)2或NR4(其中R4表示氢或取代或未取代的低级烷基;或R2和NR4组合形成取代或未取代的4 至6元饱和杂环基); A表示N或CR5(其中R5表示氢或取代或未取代的低级烷基)。

    Therapeutic agent for Parkinson's disease
    4.
    发明授权
    Therapeutic agent for Parkinson's disease 失效
    帕金森病治疗剂

    公开(公告)号:US5587378A

    公开(公告)日:1996-12-24

    申请号:US447885

    申请日:1995-05-23

    摘要: Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.

    摘要翻译: 用于治疗帕金森病的方法包括向患者施用含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐的试剂。 黄嘌呤衍生物由下式表示:其中R 1,R 2和R 3独立地是氢,低级烷基,低级链烯基或低级炔基; 并且R 4是环烷基, - (CH 2)n -R 5,其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0〜4的整数,或者,其中Y1和Y2独立地表示氢,卤素或低级烷基; Z是取代或未取代的芳基,其中R6是氢,羟基,低级烷基,低级烷氧基,卤素,硝基或氨基; m为1〜4的整数,或取代或未取代的杂环基; X1和X2独立地为O或S.

    Antidepressants
    5.
    发明授权
    Antidepressants 失效
    抗抑郁药

    公开(公告)号:US5543415A

    公开(公告)日:1996-08-06

    申请号:US199142

    申请日:1994-02-25

    摘要: The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 represent independently hydrogen, lower alkyl, lower alkenyl;R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## (in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## (in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group);and X.sup.1 and X.sup.2 represent independently O or S.

    摘要翻译: PCT No.PCT / JP93 / 00931 Sec。 371日期1994年2月25日 102(e)1994年2月25日PCT PCT 1993年7月7日PCT公布。 第WO94 / 01114号公报 日本时间1994年1月20日本发明涉及含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐的抗抑郁药,黄嘌呤衍生物由式(I)表示:其中R1,R2, 并且R 3独立地表示氢,低级烷基,低级烯基; R 4表示环烷基, - (CH 2)n -R 5(其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0〜4的整数)或

    Neural network learning device
    8.
    发明授权
    Neural network learning device 失效
    神经网络学习装置

    公开(公告)号:US5727131A

    公开(公告)日:1998-03-10

    申请号:US139710

    申请日:1993-10-22

    CPC分类号: G06N3/0454 G06N3/08

    摘要: A learning device that affects only the input-output relationships that should be additionally learned. A learning NN unit 8 capable of executing additional learning is provided separately from a learned NN unit 4 which is a basic control unit. The learned NN unit 4 produces a basic output in response to an input signal from a signal input unit 14, the learning NN unit 8 produces a correction amount desired by an individual person, and a desired control is performed based on the total value. When the output is changed, a difference is calculated between the changed output value and the basic output value from a first output unit 15, and the learning NN unit 8 executes the additional learning based upon the difference and the input value at this moment in compliance with a back-propagation method.

    摘要翻译: 仅影响应该额外学习的输入 - 输出关系的学习设备。 与作为基本控制单元的学习NN单元4分开提供能够执行附加学习的学习NN单元8。 所学习的NN单元4响应于来自信号输入单元14的输入信号产生基本输出,学习NN单元8产生个人期望的校正量,并且基于总值执行期望的控制。 当输出改变时,在改变的输出值和来自第一输出单元15的基本输出值之间计算差值,并且学习NN单元8基于此时的差异和输入值执行附加学习 具有反向传播方法。

    Xanthine derivatives
    9.
    发明授权
    Xanthine derivatives 失效
    黄嘌呤衍生物

    公开(公告)号:US5703085A

    公开(公告)日:1997-12-30

    申请号:US537770

    申请日:1995-10-20

    CPC分类号: C07D473/06

    摘要: The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2. The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).

    摘要翻译: PCT No.PCT / JP95 / 00267 Sec。 371 1995年10月20日第 102(e)1995年10月20日日期PCT提交1995年2月23日PCT公布。 公开号WO95 / 23148 日期:1995年8月31日本发明涉及由式(I)表示的新颖的黄嘌呤衍生物及其药学上可接受的盐:其中R1,R2和R3独立地表示氢,低级烷基,低级链烯基或 低级炔基,R 4表示低级烷基或取代或未取代的芳基,R 5和R 6独立地表示氢,低级烷基和低级烷氧基,或者R 5和R 6结合在一起代表-O-(CH 2)p O-(p是整数 1〜3),n表示0,1或2,m表示1或2.本发明化合物具有腺苷A2受体拮抗活性,可用于治疗或预防各种疾病 腺苷A2受体(例如帕金森病,老年性痴呆,抑郁症,哮喘和骨质疏松症)的过度高血症。

    Therapeutic purine agents for parkinson's disease
    10.
    发明授权
    Therapeutic purine agents for parkinson's disease 失效
    治疗帕金森病的嘌呤药物

    公开(公告)号:US5565460A

    公开(公告)日:1996-10-15

    申请号:US367346

    申请日:1995-03-03

    摘要: The present invention relates to a therapeutic agent for Parkinson's disease containing as an active ingredient a polycyclic compound or a pharmaceutically acceptable salt thereof, the compound being represented by the following Formula (I): ##STR1## and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl), or represented by the following Formula (II): ##STR2## wherein Y, R.sup.6 and R.sup.8 are as defined herein and B and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, partially saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group.

    摘要翻译: PCT No.PCT / JP94 / 01196 Sec。 371日期1995年3月3日 102(e)1995年3月3日PCT PCT 1994年7月20日PCT公布。 公开号WO95 / 03806 日期:1995年2月9日本发明涉及含有作为活性成分的多环化合物或其药学上可接受的盐的帕金森病治疗剂,该化合物由下式(I)表示:< IMAGE>(I)和 A表示N或CR 5(其中R 5表示氢或取代或未取代的低级烷基),或由下式(II)表示:其中Y,R 6和R 8如本文所定义,B和 相邻的两个碳原子结合形成取代或未取代的,部分饱和或不饱和的单环或双环,碳环或杂环基团。